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Object. Gamma knife surgery (GKS) may be used for recurring glioblastomas (GBMs). However, patients have then usually
undergone multimodal treatment, which makes it difficult to specifically validate GKS independent of established treatments.
Thus, we developed an experimental brain tumor model to assess the efficacy and radiotoxicity associated with GKS. Methods.
GBM xenografts were implanted intracerebrally in nude rats, and engraftment was confirmed with MRI. The rats were allocated
to GKS, with margin doses of 12Gy or 18Gy, or to no treatment. Survival time was recorded, tumor sections were examined, and
radiotoxicity was evaluated in a behavioral open field test. Results. In the first series, survival from the time of implantation was
96 days in treated rats and 72 days in controls (𝑃 < 0.001). In a second experiment, survival was 72 days in the treatment group
versus 54 days in controls (𝑃 < 0.006). Polynuclear macrophages and fibrosis was seen in groups subjected to GKS. Untreated rats
with GBM xenografts displayed less mobility than GKS-treated animals in the open field test 4 weeks after treatment (𝑃 = 0.04).
Conclusion. GKS administeredwith clinically relevant doses prolongs survival in rats harboringGBMxenografts, and the associated
toxicity is mild.
1. Introduction
The current treatments for GBMs include surgery, fraction-
ated radiotherapy (FR), and temozolomide. This approach
provides a definite effect as patients receiving thismultimodal
treatment have amedian survival of approximately 15months
[1, 2], compared with 3 months if no treatment is given.
Surgical debulking reduces symptoms and provides tissue
for diagnosis, but infiltrative tumor growth makes complete
removal impossible. Conventional radiotherapy improves
survival [3] but is associated with noteworthy toxicity due
to the high doses delivered to the surrounding brain tissue.
Thus, patients surviving more than 12 months often exhibit
significant cognitive deficits. Due to the improved survival
of GBM patients in recent years with two year survival rates
of 26.5%, more people will live to experience these side
effects [4]. As such, optimized radiation modalities to reduce
toxicity are warranted. Future treatments may include lower
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dose FR combined with hypofractionated stereotactic radio-
surgery and additional tumor selective radiosensitizers. To
explore innovative regimens for treating malignant glioma,
a representative animal model is needed.
GKS enables the delivery of a high tumor dose in one
single fraction by converging multiple beams to a stereotacti-
cally defined target, creating a sharp dose fall-off at the tumor
margin with minimal radiation to the surrounding brain [5].
GKS is not used in the primary treatment of GBMs, but there
are several reports describing its use for GBM recurrences
in patients that have already received primary treatment,
including FR [6–9]. Thus, little is known about the effects
specifically associated with GKS.
However, most GBM recurrences are local, suggesting
a role for focused radiation [10]. Moreover, experimental
studies suggest a therapeutic benefit with focused radiation
of rats implanted with rat C6 and rat 9L glioma cells [11, 12].
These rat glioma cell lines however, do not mimic the infiltra-
tive growth of human GBMs. Furthermore, previous animal
studies have involved treatment with lateral and posterior-
anterior plain X-rays [11] or additional therapies such as
injection of viral vectors [12]. Thus, there remains a need
to evaluate the radiobiology of GKS with clinically relevant
doses in tumor models that mimic the infiltrative growth of
human GBMs. We previously established highly infiltrative
brain tumors in nude rats from human GBM biopsies [14].
Direct xenografting of patient GBM biopsies into nude rats
has been shown to produce tumors with infiltrative growth
patterns without angiogenesis, similar to low-grade glioma
[13]. Serial passaging of these tumors in vivo transforms
purely invasive phenotypes into mature GBM phenotypes
that are also angiogenesis-dependent and necrotic [13, 14]. In
this study, we used this highly representative GBM model to
evaluate the effect of GKS treatment on survival, local tumor
control, and radiotoxicity.
2. Material and Methods
2.1. Tumor Spheroids. GBM biopsies were obtained during
surgical resections performed at the Department of Neuro-
surgery at Haukeland University Hospital (Bergen, Norway),
with informed consent from the patients and approval by
the regional ethical committee. The biopsy spheroids were
prepared as described previously [15] and passaged for several
generations in immunodeficient rats [13]. Tumor spheroids
were prepared from two GBM patients, pA and pB.
2.2. Animal Experiments. In total, 39 male and female
athymic, homozygous nude rats (rnu/rnu, Rowett) between
200 and 250 g were used in 3 different experiments (Table 1).
They were kept on a standard pellet diet, in a pathogen free
environment at a constant temperature and humidity, on
a standard 12/12 h light and dark cycle. The animals were
provided a standard pellet diet and tap water ad libitum.
All experimental procedures were approved by the Norwe-
gian Animal Research Authority (Oslo, Norway). Prior to
implantation, all animals were anesthetized with Isoflurane
gas (1.5% mixed with 50% air and 50% O
2
) and 0.5%
Table 1: Overview with characteristics of the animal experiments
conducted.
Experiment Biopsy Design Radiation dose Animals No.
No. 1 pA therapeutic 12 and 18Gy 21
No. 2 pB therapeutic 12Gy 9
No. 3 pA open field test 12Gy 9
Marcaine subcutaneously. Intracranial tumor implantations
were conducted with a stereotactic frame (Kopf instruments,
Tujunga, CA, USA) as previously described [14].
In the first experiment, animals with comparable tumor
volumes derived from a patient GBM xenograft, pA, were
randomly assigned to 3 different groups: (1) GKS with
12Gy margin dose; (2) GKS with 18Gy margin dose; and
(3) untreated controls. In the second experiment, we used
another GBM xenograft, pB, and the animals were random-
ized to two groups: (1) GKS with 12Gy margin dose and (2)
untreated controls. Finally, 6 animals were grafted with pA
tumor material in a separate experiment to assess radiotoxic-
ity (see Section 2.6 describing the open field study). Animals
were inspected daily by the staff at the animal facility that
were blinded to the treatments the animals had undergone.
Animals were sacrificed with CO
2
at the onset of symptoms
such asweight loss, neurological deficits, passiveness, or other
signs of illness. All animals were observed until the onset of
symptoms or until 165 days after implantation. The brains
were removed and fixed in 4% formalin. Survival was used
as primary endpoint and histological changes and volume
changes onMRI follow-upwere used as secondary endpoints.
2.3. Magnetic Resonance Imaging. Animals implanted with
pA and pB tumor spheroids underwent MRI scanning 6
and 7 weeks after implantation, respectively, using a Bruker
Pharmascan 7 T small animal MRI (Bruker Biospin MRI
GmnH, Ettingen, Germany). Animals implanted with pB
GBM spheroids in the second experiment also underwent a
repeated scanning one week later. Axial T1 and T2 weighted
images were acquired as previously described [14].The tumor
volumes at treatment and on follow-up MRI were measured
in Gamma Plan (Elekta Instrument AB, Stockholm, Sweden).
2.4. Gamma Knife Treatment. Animals were irradiated with
the Leksell Gamma Knife Perfexion (Elekta Instrument
AB, Stockholm, Sweden) anesthetized with intramuscular
Hypnorm-Dormicum (0, 4mL/kg). One day after MRI, the
rats were immobilized in a Regis-Valliccioni stereotactic
frame 5 (Neuropace, Neuilly, France (Figure 1(a))) [16]
and underwent CT scanning with the frame attached. The
MRI images of the tumors were coaligned with the CT
scans in the Gammaplan, aided by anatomical landmarks
and the visible trajectory from the tumor implantation
(Figure 1(b)). The rats were randomized to different
treatment groups and treated with a tumor margin dose of
12Gy or 18Gy to the 50–88% (mean 74.6%) isodose, using
collimator size 4 (Figure 1(c)), or they were randomized to
no treatment. The mean treatment time was 5.0 minutes.
In the radiotoxicity experiment, the rats received early
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Figure 1: GKS of nude rats harboring GBM xenografts. The rats are fixed in a stereotactic frame (a) attached to a transparent hood prior CT
scanning (b).These scans aremerged withMRI images (c). Shown is a dose administered with a 4mm collimator (red) and the accompanying
80% isodose curve (yellow).
GKS only 9 days after implantation to allow for a long
follow-up time. These animals received 12Gy to the 80%
isodose, centered at the site of the implantation (Figure 1(c)).
2.5. Histology and Immunohistochemical Analyses. Tissue
blocks were paraffin embedded and 5 𝜇m sections were
obtained. These were stained with haematoxylin and eosin
and examined by a neuropathologist. Sections were prepared
as described previously [13] and immunostained for Nestin
(1 : 1000, Chemicon, Temecula, CA, USA), Vimentin (1 : 500,
DAKO, Glostrup, Denmark), and Ki-67 (MIB-1, 1 : 500,
Dako). Cell death was determined using the terminal
transferase-mediated dUTP nick-end-labeling (TUNEL)
method according to the manufacturer’s instructions
(Boehringer Mannheim, Mannheim, Germany) using
DAB as a chromogen. TUNEL staining was quantitated
as % immunopositive area fraction at 400x magnification,
using a Nikon light microscope (THP Eclipse E600, Nikon
Corporation, Tokyo, Japan) and the NIS-Elements BR 4.0
software (Nikon Corporation). Four hotspot fields of view
were analyzed per animal from each treatment group and
control group and quantified by a person blinded to the
groups.
2.6. Open Field Experiment. In order to evaluate locomotor
and exploratory behavior deficits as a measure of radiotox-
icity, we performed an open field test 2 days and 4 weeks
after randomization to treatment or no treatment: (1) GKS
after tumor implantation (3 animals); (2) no treatment after
tumor implantation (3 animals); and (3) controls with no
tumor nor treatment (3 animals). The open field behavioral
test was developed by Calvin S. Hall [17], and measures
general locomotor activity and willingness to explore in
rodents. The field consists of a square black box, 1m× 1m
with 40 cm high walls. All animals were placed in the centre
of the open field arena and the animals’ spontaneous activities
for 9 minutes were digitally recorded. Latency to enter the
periphery (indicative of anxiety) and central zone, angular
velocity, which is the animals’ ability to turn in a specific
direction, general mobility, and time spent in left or right part
of the box were measured.
2.7. Statistical Methods. Animal survival was registered from
the time of implantation and from the time of treatment.
Survival was plotted on a Kaplan-Meyer survival curve, and
median survival times were compared using the log-rank
4 BioMed Research International
test in SPSS version 18.0. Univariate analyses of categor-
ical variables according to treatment group (12Gy versus
18Gy), 12 Gy volume outside the tumor (<30mm3 versus
>70mm3), maximum dose (<20Gy versus >20Gy), tumor
volume (<5mm3 versus 5–15mm3 versus >15mm3), and the
percentage isodose used during treatment (<80% isodose
curve versus >80% isodose curve) were conducted. Tumor
volumes on T1 weighted MRI images on the day of the
treatment and follow-up images were measured based on
the contrast-enhancing areas to detect differences in tumor
volumes, and the treatment groups were compared using
Student’s t-test. Ki-67 labeling and apoptotic indices were
analyzed using ANOVA. The open field experiments were
analyzed using ANOVA for repeated measures and the post
hoc Fisher LSD test. A probability value ≤0.05 was regarded
significant.
3. Results
3.1. Survival. In the first experiment using pA GBM
xenografts, 8 rats received a 12Gymargin dose (mean volume
12.0 ± 7.9mm3), 7 rats received an 18Gy margin dose (mean
volume 8.6 ± 5.9mm3), and 6 rats served as controls (mean
volume 10.0 ± 6.7mm3, 𝑃 < 0.65). The median survival
from the time of implantation was 96 days (95% CI 78.3–
113.7) for the two treatment groups collectively, compared
to 72 days (95% CI 68.6–75.4) for the untreated rats (𝑃 <
0.0001, Figure 2(a)). The median survival from the time of
GKS was 41 days (95% CI 23.3–58.6) for the GKS treated
rats compared to 10 days (95% CI 6.6–11.4) for the untreated
rats (𝑃 < 0.0001, Figure 2(b)). Notably, the median survival
time both from implantation and from the time of treatment
was significantly longer for animals treated with 12Gy (131
days from implantation, 72 days from GKS), compared to
animals treated with a 18Gy margin dose (84 days and 22
days, respectively, 𝑃 < 0.001, Figures 2(c) and 2(d).
The rats treated with an 18Gy margin dose had a mean
maximum dose of 23.0 ± 1.7Gy, whereas the rats treated
with a 12Gy margin dose had a mean maximum dose of
15.5 ± 1.9Gy (𝑃 < 0.001). Furthermore, for the rats receiving
18Gy the mean 12Gy volume outside the tumor was 77.9 ±
10.7mm3 versus 20.7 ± 7.7mm3 for the rats receiving 12Gy
(𝑃 < 0.001). Amultivariate analysis according tomargin dose
and adjusted for maximum dose, tumor volume, and volume
of normal brain receiving >12Gy confirmed a significantly
longer survival in the 12Gy group (𝑃 < 0.02).
In the second series, spheroids from the pB GBM
xenograft produced a more rapid disease course than the
pA tumors (Figures 2(e) and 2(f)). At the time of GKS 7
weeks after implantation, the tumors had reached a bigger
volume than in the first series. The tumors were treated with
12Gy to the periphery. The mean volume for the pB tumors
was 120mm3 (versus 10.3mm3 for the pA tumors), with no
significant differences between the 4 treated animals and the
5 controls. However, even for these late stage tumors, median
survival was significantly longer for the GKS treatment group
both from the time of implantation, 72 days versus 54 days
(𝑃 = 0.006, Figure 2(e)), and fromGKS, 12 days versus 5 days
(𝑃 = 0.006, Figure 2(f)).
3.2. MRI Monitoring of Tumor Growth. In the second exper-
iment, with pB tumors, MRI performed 8 days after the
initial MRI showed a larger increase in tumor volume for
the untreated controls compared to rats subjected to GKS
(Figure 3). The mean difference in tumor volumes between
baseline and follow-up was 111.8mm3 for the 12Gy group
versus 252.8mm3 for the controls (𝑃 = 0.032). The tumors
increased in volume by a factor of 2.9 for the controls versus
a factor of 2.1 for the treated rats.
3.3. Tumor Histology. Both the pA and pB GBM xenografts
produced tumors in all rats that were implanted. The pA
tumors showed predominantly infiltrative growthwith exten-
sive cellular infiltration throughout the brain, whereas the
pB tumors predominantly displayed microvascular prolif-
eration with necrosis (Figures 4(a) and 4(b)). Brains from
the treatment groups also showed histological changes sug-
gesting granulomatous cerebral angiitis with polynuclear
macrophages in the perivascular space, tumor cells in the
Virchow-Robin space, and fibrosis (Figure 4(a), upper right
panel). Notably, the number of microscopic fields (×10) with
the presence of granulomatous angiitis were significantly
higher in the group receiving 18Gy (49%) compared to the
group receiving 12Gy (8%, 𝑃 = 0.02).
Recently, several studies have suggested that cancer stem
cells mediate radioresistance in gliomas [18–20]. Thus, we
investigated the expression of stem cell markers Nestin and
Vimentin (Figure 4(b)). We observed Nestin and Vimentin
expression in the treatment groups as well as the controls,
both in the tumor bulk and the invasion zone. Labeling index
for the proliferation marker Ki-67 did not differ significantly
between any of the groups. In the first experiment, control
tumors displayed 18 ± 2.0% Ki-67 positive cells, tumors
treated with 12Gy contained 19±3.9% positive cells, whereas
18Gy treated tumors had 18 ± 0.7% Ki-67 positive cells (𝑃 =
0.99). Apoptosis estimated by % area fractions of TUNEL-
positive staining did not show an increase with radiation dose
and were 0.87% for the controls, 0.204 for the 12Gy group,
and 2.210 for the 18Gy group, (Figure 4(b), right panels).
3.4. Open Field Test. In order to evaluate radiotoxic side
effects, we performed an open field test two days and four
weeks following treatment (Figure 5). We compared the
activity and exploratory behavior of rats with GBM receiving
GKSwith the behavior of both untreated rats harboringGBM
tumors and untreated rats without tumors (controls). Two
days after GKS, the treated rats had a longer latency to enter
the periphery zone (𝑃 = 0.005) and seemed less active in
the open field (𝑃 = 0.09) than untreated rats with tumors.
After 4 weeks, all rats with tumors were less mobile than the
controls. Notably, the latency formoving to the outer ringwas
longer in the untreated rats with tumors than the treated rats
with brain tumors (𝑃 = 0.04) and the controls with no tumor
(𝑃 = 0.002).
BioMed Research International 5
100
75
50
25
0
Su
rv
iv
al
 (%
)
0 50 100 150 200
Time (days)
Control
Treatment
(a)
100
75
50
25
0
Su
rv
iv
al
 (%
)
0 50 100
Time (days)
Control
Treatment
(b)
100
75
50
25
0
Su
rv
iv
al
 (%
)
0 50 100 150 200
Time (days)
Control
12Gy
18Gy
(c)
100
75
50
25
0
Su
rv
iv
al
 (%
)
0 50 100
Time (days)
Control
12Gy
18Gy
(d)
Su
rv
iv
al
 (%
)
Time (days)
100
80
60
40
20
0
0 25 50 75 100
Control
12Gy
(e)
Time (days)
Su
rv
iv
al
 (%
)
100
80
60
40
20
0
0 10 20 30 40 50
Control
12Gy
(f)
Figure 2: GKS prolongs survival in nude rats harboring GBM xenografts. Shown are the treatment groups as indicated for the experiment
using pA (a–d) and pB (e) and (f) GBM xenografts. Treated rats (both 12 and 18Gy collectively) versus controls from the time of implantation,
(a) and from the time of treatment (b). Comparison of the individual treatment groups from the time of implantation (c) and from the time
of treatment (d). Survival from the time of tumor (pB) implantation (e) and from the time of treatment (f).
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Figure 3:MRI imaging demonstrates reduced tumor growth followingGKS treatment. Shown areT2-sequences, with tumor lesion presenting
as a high signal intensity area, compared to the surrounding brain. Untreated rat brain tumor (left) and tumor receiving 12Gy margin dose
(right) at the day of treatment (a). Untreated rat brain tumor (left) and GKS treated tumors (right) one week after treatment (b). The yellow
line indicates the location of the 12Gy dose at the time of treatment.
4. Discussion
The potential for GSK in GBM management has so far not
been fully elucidated, whereas the Stupp regime is widely
adapted as a first line of treatment. However, GSK can be
useful for small, deep seated, or recurrent tumors. Herein we
assessed the efficacy of GSK treatment and its potential toxi-
city in a relevant model of GBM in nude rats. We established
that GSK treatment prolonged survival of animals and that
this was associated withminimal toxicity as indicated bymild
histological and behavioral changes.
The accuracy of the Regis-Valliccioni frame has been
documented previously [21, 22]. Moreover, the precision of
12 and 18Gy dose delivery in our study was verified firstly
by the presence of radiation-induced changes in the isodose
center on histological examination in the rats receiving GKS
and secondly by reduced tumor growth on follow-up MRI.
Previously, Kondziolka et al. reported prolonged survival
after GKS for C6 glioma in rats receiving margin doses in
the range of 30–100Gy [11], whereas the survival seemed
independent of the dose given. Khil et al. found a dose-
dependent improvement in survival using margin doses of
25Gy, 35Gy, and 44Gy in rats with 9L glioma cells [23]. How-
ever, these experiments included non-human, chemically
induced glioma cell lines treated with high doses which can-
not be administered clinically in single fraction stereotactic
radiosurgery to previously irradiated patients. Accordingly,
there remains a need to evaluate the radiobiological effects
of GKS with doses relevant to the clinical setting of tumor
relapse in a patient that has previously received FR.
In this study, GBM xenografts derived from patient
tumors displayed the typical morphology of human GBMs,
including infiltrative growth, florid angiogenesis, and
necrotic regions. Moreover, the tumors were visible on MRI
at the time of treatment, resembling the treatment setting
in patients. In clinical studies validating the use of GKS for
tumor recurrences in GBM patients, the doses have varied
between 12 and 18Gy [6–8]. Therefore, we selected 12Gy and
18Gy as representative clinical doses for our experiments.
Our data demonstrate that monotherapy with GKS using
clinically relevant doses prolongs survival. With a similar
efficacy in patients, GKS may be an alternative to surgery
in cases with deep seated small GBMs, when a diagnostic
biopsy has been performed in patients who are otherwise
unable to undergo a full craniotomy under narcosis due to
severe comorbidity. Although most GBMs are too large for
GKS at the time of diagnosis, GKS could be preferable to
conventional radiotherapy in the initial treatment of small
BioMed Research International 7
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Figure 4: H/E and IHC staining of GBM xenografts. H/E staining of the tumors (a) which appear hypercellular, but with more prominent
angiogenesis and necrosis in the pB GBM xenografts (lower panels). Granulomatous cerebral angiitis with polynuclear macrophages in the
perivascular space can be seen in the pA GBM xenograft treated with 18Gy (Upper right panel). Scale bars: 50𝜇m. IHC and TUNEL staining
(brown) show robust expression of Nestin, Vimentin, and Ki-67 and TUNEL positive cells. Panels at low magnification show Nestin positive
cells in the pA xenograft migrating along the Corpus Callosum (b). Scale bars pA: Nestin 250 𝜇m, Vimentin: 100 𝜇m, Ki-67 from pA ctrl:
100𝜇m, all other panels: 25𝜇m. Scale bars pB: Nestin and Vimentin: 100 𝜇m, all other panels: 50𝜇m.
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Figure 5: Behavioral open field study comparing rats harboring
GBM xenografts with and without GKS treatment, as well as
controls. Graphic presentation of latencies to enter the periphery for
nude rats, 2 days and 4 weeks after treatment. Three animals were
tested from each group as indicated.
tumors due to a sharper dose fall and less toxicity [24].
Moreover, GKS in combination with lower, less toxic doses
of conventional radiotherapy may improve future results.
Interestingly, rats treated with 12Gy to the tumor margin
lived significantly longer survival than rats treated with
an 18Gy margin dose. The reduced survival in the 18Gy
group could be caused by edema and radiation damage to
adjacent brain tissue as a considerable volume of normal
brain received more than 12Gy in this group, which is seen
as the limit for radiation damage of the normal human brain
[25]. Polynuclear macrophage clusters in the perivascular
space andfibrosis as seen in radiation induced granulomatous
cerebral angiitis were found in the 18Gy rats. Moreover,
increased radiation injury with the 18Gy treatments may
trigger immune-mediated damage of healthy nervous tissue.
However, it should be pointed out that even the 4mm
collimator becomes a crude tool for dose delivery, given the
small rat brain volumes. Therefore, the extratumoral 12Gy
volumes in these animals are relatively much larger than
in patients, and the observed toxicity may therefore have a
very limited relevance to the clinical setting. In open field
studies, animals with untreated tumors, animals treated with
12Gy, and controls were tested. The rats treated with 12Gy
fared better than rats with untreated tumors. In addition, rats
treated with 12Gy improved from 2 days to 4 weeks after
GKS, showing a shorter latency for moving to the outer ring
of the open field arena after the start of the test. The data
indicate a positive long-lasting effect of the treatment on rats’
locomotor behavior. These animals readily started moving
around, whereas animals receiving no treatment responded
with more immobility or freezing in the start of the test.
The latency to the outer zone showed large variation between
individuals; however, the effects of the treatment on this
parameter were robust compared to animals with untreated
tumors. Thus, GKS using the 12Gy dose seemed to have
low toxicity with little impact on behavior. Notably, controls
without tumor and no treatment also performed significantly
better than untreated rats with tumors. Thus, the impact of
the location of tumors on the locomotor behavior of the
animal is likely as important as GKS.
5. Conclusion
We conclude that GKS administered as monotherapy with
clinically relevant doses prolongs survival with low associated
toxicity in rats harboring GBM xenografts. This in vivo
nude ratmodel displays tumor implants highly representative
of human GBMs. Moreover, the precision of dose delivery
was verified by reduced tumor growth and the presence of
radiation-induced histological changes in the rats subjected
to GKS. The model described represents a valuable tool for
future small animal studies. Additional studies on potential
drug modification of the radiosurgery response in human
GBM are warranted.
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